Recent studies have provided strong evidence that blocking the activity of isoprenylcysteine carboxyl methyltransferase by genetic disruption has profound consequences on oncogenic transformation and limits the proliferation of cancer cells, thus rendering this enzyme an attractive target for anti-cancer drugs [76,77]. The gene discussed is ICMT; the disease is cancer.